Investigational Drug Information for KHK7580
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for KHK7580?
KHK7580 is an investigational drug.
There have been 9 clinical trials for KHK7580.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 29th 2015.
The most common disease conditions in clinical trials are Hyperparathyroidism, Hyperparathyroidism, Secondary, and Neoplasm Metastasis. The leading clinical trial sponsors are Kyowa Kirin Co., Ltd., Kyowa Hakko Kirin Co., Ltd, and Kyowa Hakko Kirin Company, Limited.
There are four US patents protecting this investigational drug and thirty-nine international patents.
Summary for KHK7580
| US Patents | 4 |
| International Patents | 39 |
| US Patent Applications | 5 |
| WIPO Patent Applications | 3 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 3 (2015-09-29) |
| Vendors | 17 |
Recent Clinical Trials for KHK7580
| Title | Sponsor | Phase |
|---|---|---|
| Pharmacokinetic Study of KHK7580 in Healthy Adult Volunteers | Kyowa Hakko Kirin China Pharmaceutical Co., LTD. | Phase 1 |
| Pharmacokinetic Study of KHK7580 in Healthy Adult Volunteers | Kyowa Kirin Co., Ltd. | Phase 1 |
| Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia | Kyowa Hakko Kirin China Pharmaceutical Co., LTD. | Phase 3 |
Clinical Trial Summary for KHK7580
Top disease conditions for KHK7580
Top clinical trial sponsors for KHK7580
US Patents for KHK7580
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| KHK7580 | See Plans and Pricing | Pharmaceutical composition containing an arylalkylamine compound | KYOWA HAKKO KIRIN CO., LTD. (Chiyoda-ku, JP) | See Plans and Pricing |
| KHK7580 | See Plans and Pricing | Arylalkylamine compound and process for preparing the same | Mitsubishi Tanabe Pharma Corporation (Osaka-Shi, JP) | See Plans and Pricing |
| KHK7580 | See Plans and Pricing | Arylalkylamine compound and process for preparing the same | Mitsubishi Tanabe Pharma Corporation (Osaka, JP) | See Plans and Pricing |
| KHK7580 | See Plans and Pricing | Crystalline 4-(3S-(1R-(1-napthyl)ethylamino)pyrrolidin-1-yl)phenylacetic acid | MITSUBISHI TANABE PHARMA CORPORATION (Osaka, JP) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for KHK7580
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| KHK7580 | China | CN108135883 | 2035-10-07 | See Plans and Pricing |
| KHK7580 | European Patent Office | EP3360551 | 2035-10-07 | See Plans and Pricing |
| KHK7580 | Japan | JP2017071599 | 2035-10-07 | See Plans and Pricing |
| KHK7580 | Japan | JP2017071605 | 2035-10-07 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
